Cargando…
gsp Mutation Is Not a Molecular Biomarker of Long-Term Response to First-Generation Somatostatin Receptor Ligands in Acromegaly
SIMPLE SUMMARY: Acromegaly treatment consists of surgical, medical, and radiation therapy. First-generation somatostatin receptor ligands are the mainstay of medical therapy, with approximately 40% disease control rate. Several parameters have been evaluated as predictors of response to these drugs,...
Autores principales: | Wildemberg, Luiz Eduardo, Henriques, Daniel, Elias, Paula C. L., Lima, Carlos Henrique de A., Musolino, Nina R. de Castro, Camacho, Aline Helen Silva, Faria, Olivia, Nazato, Debora, Abucham, Julio, Vilar, Lucio, Mota, Jose Italo, Huayllas, Martha Katherine P., Chimelli, Leila, de Castro, Margaret, Kasuki, Leandro, Gadelha, Mônica R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508484/ https://www.ncbi.nlm.nih.gov/pubmed/34638340 http://dx.doi.org/10.3390/cancers13194857 |
Ejemplares similares
-
The Future of Somatostatin Receptor Ligands in Acromegaly
por: Gadelha, Monica R, et al.
Publicado: (2021) -
Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles
por: Coelho, Maria Caroline Alves, et al.
Publicado: (2019) -
miR-383-5p, miR-181a-5p, and miR-181b-5p as Predictors of Response to First-Generation Somatostatin Receptor Ligands in Acromegaly
por: Henriques, Daniel G., et al.
Publicado: (2023) -
MicroRNA in Acromegaly: Involvement in the Pathogenesis and in the Response to First-Generation Somatostatin Receptor Ligands
por: Henriques, Daniel G., et al.
Publicado: (2022) -
Brazilian multicenter study on pegvisomant treatment in acromegaly
por: Boguszewski, Cesar L., et al.
Publicado: (2019)